⌘K
Loading ticker…
Savara Inc. · Healthcare · Pharmaceutical Products
As of 2026-06-26, Savara Inc. (SVRA) has a 3-month relative strength percentile of 61 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 65. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 5.3%, relative volume 3.15×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
61 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
SVRA is in a stage 3 topping pattern, week 6. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 12.3% / 14.9%.
No attention data for this ticker yet — it joins the daily scan once a baseline builds.
SVRA is held by 6 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $33M notional. Top 3 carry $72M.
Top 6 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $33M |
| IWMiShares Russell 2000 ETF | 0.03% | $20M |
| XBIState Street SPDR S&P Biotech ETF | 0.26% | $19M |
| VXFVanguard Extended Market ETF | 0.01% | $8M |
| IWOiShares Russell 2000 Growth ETF | 0.05% | $7M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $903K |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | SVRA Jan avg: 12.59% median: -2.67% win: 50% σ: 37.57% n: 4 2022-04-12 → 2026-05-29 | SVRA Feb avg: 0.52% median: -0.81% win: 50% σ: 8.39% n: 4 2022-04-12 → 2026-05-29 | SVRA Mar avg: -5.36% median: -5.34% win: 25% σ: 13.95% n: 4 2022-04-12 → 2026-05-29 | SVRA Apr avg: -1.73% median: -4.03% win: 20% σ: 9.90% n: 5 2022-04-12 → 2026-05-29 | SVRA May avg: 3.42% median: -0.76% win: 40% σ: 28.04% n: 5 2022-04-12 → 2026-05-29 | SVRA Jun avg: 7.69% median: 8.02% win: 50% σ: 9.74% n: 4 2022-04-12 → 2026-05-29 (current) | SVRA Jul avg: 11.59% median: 12.82% win: 100% σ: 3.46% n: 4 2022-04-12 → 2026-05-29 | SVRA Aug avg: 2.21% median: -3.03% win: 50% σ: 17.13% n: 4 2022-04-12 → 2026-05-29 | SVRA Sep avg: 5.24% median: 6.41% win: 75% σ: 4.43% n: 4 2022-04-12 → 2026-05-29 | SVRA Oct avg: -5.46% median: -8.72% win: 25% σ: 16.17% n: 4 2022-04-12 → 2026-05-29 | SVRA Nov avg: 19.41% median: 16.82% win: 75% σ: 26.11% n: 4 2022-04-12 → 2026-05-29 | SVRA Dec avg: 1.85% median: -3.02% win: 25% σ: 13.77% n: 4 2022-04-12 → 2026-05-29 |